Protocol No.: PCYC-1141-CA
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)
Study Locations in Greece:
Hematology Division – University Hospital of West Attica – Attikon, Athens
Hematology Division / First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens
Hematology Department – University General Hospital of Thessaloniki AHEPA, Thessaloniki
Hematology Department – General Hospital of Thessaloniki G. Papanikolaou, Thessaloniki
Hematology Department – General University Hospital of Larissa
Hematology Unit of Internal Medicine Dept. – University General Hospital of Patras
Protocol No.: 20130109
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)
Study Locations in Greece:
Department of Hematology, Medical School, University of Ioannina
Hematology Unit of Internal Medicine Dept. – University General Hospital of Patras
Protocol No.: MO39107
A phase II study exploring the safety and efficacy of Atezolizumab administered in combination with Obinutuzumab or Rituximab anti-CD 20 therapy in patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL),Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM)
Study Locations in Greece:
Hematology & Lymphoma, Bone Marrow Transplant Unit – Evangelismos Hospital, Athens
Protocol No.: 20150291
A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation
Study Locations in Greece:
Hematology & Lymphoma, Bone Marrow Transplant Unit – Evangelismos Hospital, Athens